AbbVie's Etentamig Hits Dual Primary Endpoints in Phase 3 Multiple Myeloma Trial
ABBV sits 37% above its 52-week low of $190.75.
Summary
AbbVie's etentamig met both primary endpoints in a Phase 3 study for triple-class exposed relapsed/refractory multiple myeloma, showing significantly higher objective response rate and improved progression-free survival versus standard therapies. This is the first disclosure of these results and marks a major advance in AbbVie's multiple myeloma strategy, which includes complementary T-cell engagers and targeted small molecules. The company plans to discuss the data with global regulators to determine next steps, positioning etentamig as a potential new treatment option in a difficult-to-treat patient population. The news follows AbbVie's recent $10.9B Apogee Therapeutics acquisition and positive regulatory developments for RINVOQ and TEPKINLY, reinforcing its oncology and immunology pipeline momentum.
Updates
· Benzinga — The CERVINO trial showed a 74% objective response rate versus 45.7% for standard therapy, and 12-month overall survival of 87.9% versus 72%, though OS data have not crossed the prespecified efficacy boundary.
At the time of this announcement, ABBV was trading at $260.55 on NYSE in the Life Sciences sector, with a market capitalization of approximately $460.4B. The 52-week trading range was $190.75 to $267.47. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.